Analytical Data
-
Gene name
EBNA1BP2
- Application
-
Alternative Names
EBNA1BP2；EBP2;Probable rRNA-processing Protein EBP2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q99848
-
Expression Region
1-306aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSMDTPPLS DSESESDESL VTDRELQDAF SRGLLKPGLN VVLEGPKKAV NDVNGLKQCL AEFKRDLEWV ERLDVTLGPV PEIGGSEAPA PQNKDQKAVD PEDDFQREMS FYRQAQAAVL AVLPRLHQLK VPTKRPTDYF AEMAKSDLQM QKIRQKLQTK QAAMERSEKA KQLRALRKYG KKVQTEVLQK RQQEKAHMMN AIKKYQKGFS DKLDFLEGDQ KPLAQRKKAG AKGQQMRKGP SAKRRYKNQK FGFGGKKKGS KWNTRESYDD VSSFRAKTAH GRGLKRPGKK GSNKRPGKRT REKMKNRTH
-
Molecular Weight
37 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EBNA1BP2, or Epstein-Barr Virus Nuclear Antigen 1 Binding Protein 2, is a protein that plays a critical role in the biology of Epstein-Barr Virus (EBV), a virus associated with various malignancies and diseases, including nasopharyngeal carcinoma and lymphoproliferative disorders. EBNA1BP2 has been identified as an essential cofactor for the stability of EBNA1, a key viral protein that ensures the replication and persistence of the EBV genome in infected cells. The interaction between EBNA1 and EBNA1BP2 is vital for the virus's latent infection and contributes to its pathogenicity. Research into the recombinant expression of EBNA1BP2 provides insights into its structural and functional properties, facilitating the development of therapeutic strategies aimed at disrupting the EBV life cycle. Understanding the molecular mechanisms by which EBNA1BP2 contributes to EBV persistence and related diseases holds promise for advancing treatments for EBV-associated conditions. Moreover, the study of EBNA1BP2 can aid in elucidating the virus-host interactions that underpin EBV's ability to evade the immune response, further emphasizing its importance in virology and cancer research. With the increasing recognition of EBV's role in various diseases, the exploration of EBNA1BP2 as a target for therapeutic intervention is becoming increasingly relevant, opening new avenues for research and potential clinical applications.
